TRVX.OL Stock Chart

Targovax is a clinical stage immuno-oncology company, which engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase I clinical trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, as well as for ovarian cancer and soft tissue sarcoma.